Dr Hubert Birner

General Partner of TVM Capital

Dr Hubert Birner, 41, has been a Member of the Supervisory Board of Evotec AG since June 2005, when Evotec had reacquired full ownership interest in Evotec Neurosciences from TVM Capital as the lead and other venture capital investors. He joined TVM Capital in 2000 and is General Partner for life sciences in the firm's Munich office. Prior to that he was Head of Business Development Europe and Director of Marketing Germany at Zeneca. Dr Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a Management Consultant, he gained extensive experience in R&D management, marketing & sales as well as joint venture structuring and business development. Dr Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies.

Dr Birner serves as Chairman of the Board of Direvo Biotech AG (Cologne, Germany), Argos Therapeutics Inc. (Durham, North Carolina, USA) and Spepharm Holdings BV (Amsterdam, Netherlands). He is also a Board Member of Jerini AG (Berlin, Germany) and BioXell SA (Milan, Italy) and represents the interests of TVM Capital at Ardana Bioscience plc (Edinburgh, UK) and Proteon Therapeutics, Inc (Kansas City, Missouri, USA). Dr Birner holds an MBA from Harvard Business School and a "summa cum laude" doctoral degree in biochemistry from Ludwig-Maximilians-University Munich. His doctoral thesis was honoured with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.